Orciprenaline


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Bronchial asthma
Adult: Dosage is individualised according to patient response. 20 mg 3-4 times daily.
Child: 6-9 years or weighing <27 kg 10 mg 3-4 times daily; >9 years or weighing ≥27 kg Same as adult dose.

Oral
Bronchospasm
Adult: For the treatment of reversible cases that may occur in association with bronchitis and emphysema. Dosage is individualised according to patient response. 20 mg 3-4 times daily.
Child: 6-9 years or weighing <27 kg 10 mg 3-4 times daily; >9 years or weighing ≥27 kg Same as adult dose.
Administration
May be taken with or without food.
Contraindications
Pre-existing cardiac arrhythmias associated with tachycardia.
Special Precautions
Patient with CV disease (e.g. ischaemic heart disease, hypertension, cardiac arrhythmias), hyperthyroidism, diabetes mellitus, glaucoma, hypokalaemia, or seizures. Not recommended for routine or long-term daily use for the management of acute asthma. Children. Pregnancy and lactation. Monitoring Parameters Monitor blood pressure, heart rate, pulmonary function tests (e.g. forced expiratory volume in 1 second [FEV1], peak flow), serum glucose, K, and CNS stimulation.
Adverse Reactions
Significant: Immediate hypersensitivity reactions (e.g. urticaria, rash, bronchospasm, angioedema), changes in systolic and diastolic blood pressure. Cardiac disorders: Tachycardia, palpitations. Gastrointestinal disorders: Nausea, diarrhoea. Musculoskeletal and connective tissue disorders: Tremor. Nervous system disorders: Headache, nervousness, dizziness, insomnia, fatigue. Respiratory, thoracic and mediastinal disorders: Exacerbation of asthma.
Overdosage
Symptoms: Arrhythmias, angina, hypertension or hypotension, palpitations, nervousness, tremor, headache, dry mouth, nausea, malaise, fatigue, dizziness, and insomnia. Management: Symptomatic treatment.
Drug Interactions
Enhanced adverse effect with other sympathomimetic agents, MAOIs, and TCAs. Diminished bronchodilatory effect with non-selective β-blockers (e.g. propranolol).
Action
Orciprenaline is a bronchodilator which exerts its effect by stimulating the β-adrenergic receptors causing an increased conversion of ATP to 3'-5'-cyclic adenosine monophosphate(cAMP) resulting to bronchial smooth muscle relaxation. Synonym: metaproterenol.
Onset: Approx 30 minutes (bronchodilation).
Duration: Approx 2-6 hours.
Absorption: Well absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 1 hour. Bioavailability: Approx 40%.
Metabolism: Undergoes extensive first-pass metabolism in the liver.
Excretion: Via urine (as glucuronic acid conjugates).
Storage
Oral: Store below 30°C. Protect from light.
CIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AB03 - orciprenaline ; Belongs to the class of adrenergic inhalants, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03CB03 - orciprenaline ; Belongs to the class of adrenergics for systemic use, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by CIMS based on orciprenaline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in